<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000970" GROUP_ID="INFECTN" ID="337699102813001181" MERGED_FROM="" MODIFIED="2008-10-26 14:01:37 +0100" MODIFIED_BY="Reive Robb" REVIEW_NO="HMWA" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-10-09 15:24:07 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Fully intermittent dosing with drugs for treating tuberculosis in adults</TITLE>
<CONTACT>
<PERSON ID="18282" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Henry</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Mwandumba</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Clinical Lecturer</POSITION>
<EMAIL_1>H.C.Mwandumba@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pharmacology &amp; Therapeutics</DEPARTMENT>
<ORGANISATION>University of Liverpool</ORGANISATION>
<ADDRESS_1>Ashton Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L69 3GE</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 794 5543</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 794 5540</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-10-08 10:41:03 +0100" MODIFIED_BY="Harriet MacLehose">
<PERSON ID="18282" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Henry</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Mwandumba</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Clinical Lecturer</POSITION>
<EMAIL_1>H.C.Mwandumba@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pharmacology &amp; Therapeutics</DEPARTMENT>
<ORGANISATION>University of Liverpool</ORGANISATION>
<ADDRESS_1>Ashton Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L69 3GE</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 794 5543</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 794 5540</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19584" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stephen</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Squire</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Clinical Tropical Medicine</POSITION>
<EMAIL_1>sbsquire@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 708 9393</PHONE_1>
<PHONE_2>+44 151 705 3101</PHONE_2>
<FAX_1>+44 151 707 9193</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-09 15:24:07 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="9" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="9" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-08 13:02:54 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-08 13:02:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-09 15:23:16 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-09 15:23:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="11" YEAR="2005"/>
<DESCRIPTION>
<P>The world 'adult' has been added to the title, synopsis, and the abstract to emphasize the fact that the review's focus is on adults with smear positive tuberculosis. The text in the 'Search strategy for identification of studies' has been revised to reflect the extent and completeness of our search for relevant studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-09 15:20:56 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="9" YEAR="2005"/>
<DESCRIPTION>
<P>New studies sought but none found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>European Commission (Directorate General XII)</NAME>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-09 15:27:11 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>There is insufficient evidence to compare equivalence of effect between fully intermittent and daily treatment in adult patients with pulmonary tuberculosis.</TITLE>
<SUMMARY_BODY>
<P>Rifampicin-containing drug combinations can achieve high cure rates in patients with pulmonary tuberculosis when given for six months. Such treatment can be given either daily or intermittently (eg three times a week) from the beginning. This review compared the equivalence of effect between such treatments but did not find enough evidence to be able to assess this.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-08 13:03:12 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>The number of people infected with tuberculosis continues to rise worldwide. Rifampicin-containing treatment regimens can achieve high cure rates. Intermittent drug treatment delivered in the community has the potential to improve adherence to treatment. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to compare the effectiveness of rifampicin-containing short-course chemotherapy regimens, given two or three times a week, with similar regimens given daily in adult patients with pulmonary tuberculosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-08 13:03:12 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group specialized trials register (January 2003), The Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> Issue 4, 2002), MEDLINE (1966 to January 2003), EMBASE (1980 to December 2002), and reference lists of articles. We contacted experts in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized and quasi-randomized trials of any multiple drug regimen containing rifampicin in patients with confirmed pulmonary tuberculosis. Treatment had to be given up to three times a week for up to nine months, with any initial daily dosing period not more than one month, and was compared to daily dosing throughout for the same period.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently assessed trial eligibility and quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>One trial involving 399 patients was included. The trial compared treatment three times per week with daily treatment for six months. There was no difference in cure rate (198 out of 199 people in the intermittent group compared to all 200 in the daily group), but 5 patients relapsed in the group receiving intermittent therapy compared to one in the group receiving the daily regimen.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to assess the equivalence of effect between fully intermittent, rifampicin-containing short-course chemotherapy and similar daily therapy in patients with pulmonary tuberculosis. Larger randomized studies are required to establish the equivalence of fully intermittent, short-course chemotherapy, with daily regimens.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-09 15:27:11 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-09 15:27:11 +0100" MODIFIED_BY="[Empty name]">
<P>The number of people infected with <I>Mycobacterium tuberculosis</I> is increasing globally (<LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>). Most people infected and ill with tuberculosis (TB) are in developing countries (<LINK REF="REF-Dolin-1994" TYPE="REFERENCE">Dolin 1994</LINK>). Human immunodeficiency virus (HIV) has contributed to the increase in TB (<LINK REF="REF-Harries-1996" TYPE="REFERENCE">Harries 1996</LINK>). Pulmonary TB is the predominant clinical presentation of this disease and sputum positive cases are the most important sources of infection in the community (<LINK REF="REF-Grzybowski-1975" TYPE="REFERENCE">Grzybowski 1975</LINK>).</P>
<P>Historically, effective drug treatment for TB lasted between 18 and 24 months. Adding rifampicin to TB treatment in 1967 helped establish short-course chemotherapy regimens lasting 6 to 9 months. Today, most of these shorter regimens contain rifampicin, are given daily (7 days a week) for the duration, and result in cure rates approaching 100% providing the disease is sensitive to the drugs and the patients adhere to treatment (<LINK REF="REF-Singapore-1981" TYPE="REFERENCE">Singapore 1981</LINK>, E&amp;C Africa 1983, <LINK REF="REF-BTS-1984" TYPE="REFERENCE">BTS 1984</LINK>). Several cohort studies conducted in Africa, East Asia, the Indian subcontinent, and Poland have suggested that equally high cure rates can be achieved with rifampicin-containing regimens which comprise an initial phase of daily treatment (usually two months) followed by intermittent treatment for a further four to six months (referred to as 'partial intermittent short-course chemotherapy').</P>
<P>When short-course chemotherapy is prescribed daily, direct supervision appears important for good adherence (<LINK REF="REF-Anonymous-1993" TYPE="REFERENCE">Anonymous 1993</LINK>, <LINK REF="REF-Weis-1994" TYPE="REFERENCE">Weis 1994</LINK>, <LINK REF="REF-Chaulk-1995" TYPE="REFERENCE">Chaulk 1995</LINK>). In the past, health providers have hospitalized patients to maintain supervision (<LINK REF="REF-Enarson-1996" TYPE="REFERENCE">Enarson 1996</LINK>). However, this option is not sustainable where limited hospital resources are further stretched by the HIV epidemic (<LINK REF="REF-Wilkinson-1997a" TYPE="REFERENCE">Wilkinson 1997a</LINK>).</P>
<P>In these circumstances, drug regimens that are 'fully intermittent', that is, where patients are only required to take drugs on three occasions or less within a week could help in ensuring delivery with direct observation (<LINK REF="REF-Wilkinson-1997b" TYPE="REFERENCE">Wilkinson 1997b</LINK>). Such fully intermittent short-course chemotherapy has the potential to reduce the requirement for prolonged hospitalization, which carries significant negative social consequences for patients. It also has the potential to improve adherence to treatment and, consequently, cure rates. It may be that such regimens commence with a daily regimen for a variable period while the patient is carefully stabilized as an inpatient on treatment. Thus this review defines fully intermittent short course chemotherapy as: (1) regimens lasting no longer than nine months, and (2) regimens in which an initial daily dosing phase does not exceed one month.</P>
<P>Data from several cohort studies suggest that fully intermittent drug administration (as defined in this review) is well tolerated and effective, with cure rates of 80 to 100% in populations where treatment is given under direct supervision for 6 to 9 months (<LINK REF="REF-Roumania-1977" TYPE="REFERENCE">Roumania 1977</LINK>, <LINK REF="REF-Dutt-1979" TYPE="REFERENCE">Dutt 1979</LINK>, <LINK REF="REF-Cohn-1990" TYPE="REFERENCE">Cohn 1990</LINK>, <LINK REF="REF-Manalo-1990" TYPE="REFERENCE">Manalo 1990</LINK>, <LINK REF="REF-Hong-Kong-1991a" TYPE="REFERENCE">Hong Kong 1991a</LINK>, <LINK REF="REF-Hong-Kong-1991b" TYPE="REFERENCE">Hong Kong 1991b</LINK>, <LINK REF="REF-Sedlaczek-1995" TYPE="REFERENCE">Sedlaczek 1995</LINK>, <LINK REF="REF-Caminero-1996" TYPE="REFERENCE">Caminero 1996</LINK>, <LINK REF="REF-China-1996" TYPE="REFERENCE">China 1996</LINK>, <LINK REF="REF-Neher-1996" TYPE="REFERENCE">Neher 1996</LINK>, <LINK REF="REF-Bechan-1997" TYPE="REFERENCE">Bechan 1997</LINK>, <LINK REF="REF-Wilkinson-1997c" TYPE="REFERENCE">Wilkinson 1997c</LINK>). However, we are not aware of any formal comparison with daily drug administration, and therefore decided to summarize evidence evaluating the effects of fully intermittent regimens (or regimens with an initial daily phase of not more than one month) compared with daily regimens.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-08-18 16:29:15 +0100" MODIFIED_BY="[Empty name]">
<P>To compare twice or thrice weekly (with or without daily therapy for the first month) with daily short-course chemotherapy (containing rifampicin) in adult patients with pulmonary tuberculosis in relation to cure, mortality, sterilizing sputum, recurrence of disease, emergence of drug resistance, adherence to treatment, and drug toxicity.</P>
<P>It was intended to explore these hypotheses if data allowed:</P>
<P>Comparative cure rates between fully intermittent and daily short course chemotherapy are independent of:</P>
<P>1. adherence to treatment;</P>
<P>2. the patient's HIV status;</P>
<P>3. previous treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-09 15:26:15 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-08 13:06:02 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Any trial in which a form of random allocation was attempted, including alternate allocation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-08 13:03:39 +0100" MODIFIED_BY="[Empty name]">
<P>Previously treated and untreated adult patients aged 16 or above, with a positive growth on culture of <I>Mycobacterium tuberculosis</I>, or one or more sputum smears positive for mycobacteria by direct or indirect microscopy.</P>
<P>Previously untreated patients were defined as those with less than 4 months of previous chemotherapy, including not more than 2 weeks during the 12 months immediately preceding the diagnosis. Patients with more than 4 months of previous chemotherapy including more than 2 weeks during the preceding 12 months were considered as having had previous treatment.</P>
<P>Standard laboratory definitions of positive growth of M. tuberculosis in laboratory culture systems (using Lowenstein-Jensen or equivalent media) were used (<LINK REF="REF-Crowle-1986" TYPE="REFERENCE">Crowle 1986</LINK>). A minimum of one sputum sample was taken as adequate for these definitions.</P>
<P>For smear microscopy, at least one sputum sample in which at least 10 acid fast bacilli were identified in 100 high power fields was taken as indicating sputum smear positivity. Smear negativity required at least 2 separate sputum samples in which no acid fast bacilli were identified following examination of 100 high power fields. Smears which had been prepared directly from the samples or following sputum concentration with a recognised technique were accepted.</P>
<P>HIV status of participants determined by a recognised testing strategy. For the purpose of this review HIV status was assumed to be negative if the trial was conducted in a community with an HIV prevalence among tuberculosis patients of &lt;5%.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-08 13:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>Both regimens should contain rifampicin for at least the initial two months of therapy, and continue for a maximum of nine months.</P>
<SUBSECTION>
<HEADING LEVEL="4">Experimental</HEADING>
<P>Intermittent short course therapy: any rifampicin-containing multiple drug regimen, administered up to three times a week for a maximum of nine months; initial daily dosing phase does not exceed one month.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparator</HEADING>
<P>Daily short course chemotherapy: any rifampicin-containing regimen given daily throughout for a maximum of nine months.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-18 16:30:22 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>Cure</LI>
<LI>Proportion of participants with a negative sputum culture (or two negative sputum smears) within one month of completion of treatment.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Death</LI>
<LI>Death while on treatment and up to 12 months after treatment.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sterilizing efficacy</HEADING>
<UL>
<LI>Proportion of participants with a negative sputum culture (or two negative smears) two months after start of treatment.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Recurrence of disease</HEADING>
<UL>
<LI>Proportion of participants with a single positive sputum culture (or 1 positive smear if symptomatic) within 12 months of cure (as defined above). The 12 month cut-off was chosen because a significant proportion of recurrent disease within this time frame may reasonably be attributed to relapse (ie therapeutic failure). Beyond 12 months, recurrent disease is increasingly likely to be due to reinfection, depending on the country prevalence of infection.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Drug resistance</HEADING>
<UL>
<LI>Proportion of participants developing in vitro drug resistance while on treatment. It is recognised that the interpretation of the laboratory methods used in assessing in vitro drug resistance (such as ID50 [infective dose for 50% of the population] versus MIC [minimum inhibitory concentration]) is complicated. For this reason, details of laboratory methodology were scrutinized before assessing the validity of in vitro resistance data, if present.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Drug toxicity</HEADING>
<UL>
<LI>Proportion of participants experiencing adverse drug reactions requiring interruption or alteration of the drug regimen.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Non-adherence</HEADING>
<UL>
<LI>The proportion of participants who discontinue therapy of their own accord for at least one month.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-08 13:06:23 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<P>The Cochrane Infectious Diseases Group specialized trials register was searched for relevant trials up to January 2003 using the search terms: 'tuberculosis', 'rifampin', and 'rifampicin'. As our definition of short-course chemotherapy is "any rifampicin-containing regimen lasting 9 months or less". The terms rifampin (USA terminology) or rifampicin (European terminology) were used, and this was more sensitive than the term 'treatment'. Full details of the Cochrane Infectious Disease Group methods and the journals hand searched are published in <I>The Cochrane Library </I>in the section on Collaborative Reveiw Groups.</P>
<P>We searched The Cochrane Controlled Trials Register, published in <I>The Cochrane Library </I>(Issue 4, 2002) using the search terms: 'tuberculosis', 'rifampin', and 'rifampicin'. This contains mainly reference information to randomized controlled trials and controlled clinical trials in health care.</P>
<P>The following databases were also searched using the earch terms in combination with the search strategy developed by The Cochrane Collaboration and detailed in the Cochrane Reviewers' Handbook (<LINK REF="REF-Clarke-2002" TYPE="REFERENCE">Clarke 2002</LINK>): MEDLINE (1966 to January 2003); and EMBASE (1980 to December 2002).The search terms used were: tuberculosis (textword or MESH heading), rifampin or rifampicin (textword), and rifampin (MESH heading).</P>
<P>Organizations and individual researchers working in the field were contacted for unpublished data, confidential reports, and raw data of published trials. These included the World Health Organization, the International Union Against Tuberculosis and Lung Disease, and the British Medical Research Council.</P>
<P>External referees were asked to check the completeness of the search strategy, and the efforts made to identify unpublished, ongoing, and planned trials.</P>
<P>We also checked the citations of existing reviews and of all trials identified by the above methods.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-09 15:26:15 +0100" MODIFIED_BY="[Empty name]">
<P>The inclusion criteria were applied by the two reviewers independently and differences resolved by discussion. Data on study methods, participants, interventions, and outcomes were collected for each study. Quality of allocation concealment, allocation sequence generation, and follow-up of participants were assessed in each trial, using the guidelines of the Cochrane Infectious Diseases Group. Data on outcomes after the interventions were compared using the risk ratio (RR) and 95% confidence intervals (CI).</P>
<P>Subgroup analysis was conducted between fully intermittent and daily short course chemotherapy in order to explore potential heterogeneity:</P>
<P>1. adherent and non-adherent patients (patients judged to have completed the full course of therapy without missing more than 28 consecutive days of treatment were defined as adherent. Patients who did not fulfil this definition were defined as non-adherent);</P>
<P>2. HIV positive and HIV negative patients;</P>
<P>3. previously treated and untreated patients.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-08 13:09:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-08 13:08:55 +0100" MODIFIED_BY="[Empty name]">
<P>One study by the Hong Kong Chest Service / British Medical Reserch Council (<LINK REF="STD-Hong-Kong-1981" TYPE="STUDY">Hong Kong 1981</LINK>) included a concurrent comparison of fully intermittent with daily short course chemotherapy and met the inclusion criteria (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). The study randomized 1207 adults with smear positive, culture confirmed pulmonary tuberculosis to 5 different short course regimens.</P>
<P>One comparison was between daily isoniazid, rifampicin, pyrazinamide, and ethambutol for six months and the same drugs administered three times a week from the start for six months. All drugs were administered by clinic staff under direct supervision. Patients with a history of antituberculous chemotherapy (more than 4 months in total or more than 2 weeks in the preceding 12 months) were excluded. Outcomes were stratified for patients with pretreatment strains showing resistance to at least one drug (there were no true multiple drug resistant cases) and patients with pretreatment strains that were fully sensitive. No HIV serology was carried out as the study took place before international recognition of the HIV pandemic.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The <LINK REF="STD-Hong-Kong-1981" TYPE="STUDY">Hong Kong 1981</LINK> study was described as randomized but the method of allocation concealment and randomization was not given. Trial participants were not blinded to the therapy allocated and blinding of assessors was not described. </P>
<P>The paper does not report whether all the participants meeting the entry criteria were enrolled but exclusions after randomization and losses to follow-up are detailed. Exclusions were for reasons present before treatment (such as pretreatment sputum cultures were negative or prolonged duration of previous chemotherapy) or arising during treatment (eg missed at least six weeks of treatment because of drug toxicity). </P>
<P>In the fully intermittent comparison, 242 participants were randomized, and in the daily treatment group, 239 were randomized. This includes participants with both pretreatment drug sensitive and drug resistant strains. 29 (12%) were excluded and 14 (6%) lost to follow-up from the fully intermittent arm, while 33 (14%) were excluded, and 6 (3%) were lost to follow-up from the daily treatment arm.</P>
<P>An 'intention-to-treat' analysis was not employed.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-08 13:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>In the <LINK REF="STD-Hong-Kong-1981" TYPE="STUDY">Hong Kong 1981</LINK> study, bacteriological cure rates were reported as 99.5% (198/199) in the fully intermittent arm and 100% (200/200) in the daily arm (95% CI 0.90 to 1.10; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). One patient was not cured in the fully intermittent arm and died during the fifth month of chemotherapy giving a mortality of 0.5% in this arm compared with 0% in the daily treatment arm (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>There were more recurrences in the fully intermittent arm compared with the daily treatment, but this was not statistically significant (5/186 (3%) compared to the 1/192 (0.5%) (RR 4.00, 95% CI 0.66 to 24.10; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The development of in vitro drug resistance was not identified in either arm despite monthly sputum cultures for 18 months from the start of chemotherapy (see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Adherence was reported as 100% in both arms and verified by urine testing for isoniazid (see <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Adverse events led to the interruption of drug therapy or the termination of 1 or more drugs in 12% (30/241) of participants while on fully intermittient compared to 13% (30/239) on the daily regimen (see <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). This comparison includes patients who were randomized, but excluded from the bacteriological analyses because drug therapy was interrupted for more than 6 weeks.</P>
<P>When participants with pretreatment drug sensitive strains were compared with those with pretreatment drug resistant strains, no differences with respect to cure, adherence to treatment, drug toxicity, and emergence of drug resistance were detected. Only one patient in the fully intermittent arm with pretreatment drug resistance died during the fifth month of chemotherapy. Five patients with drug sensitive strains pretreatment had recurrent disease (4/164 in the fully intermittent arm, 1/161 in the daily arm). Only one patient in the fully intermittent arm with pretreatment drug resistance had recurrent disease and there were no recurrences in the daily treatment arm.</P>
<P>Sterilizing capacity could not be compared because data on sputum smear and culture rates two months following the start of chemotherapy were not presented for the whole study population.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-08 13:03:46 +0100" MODIFIED_BY="[Empty name]">
<P>The <LINK REF="STD-Hong-Kong-1981" TYPE="STUDY">Hong Kong 1981</LINK> study shows equally high bacteriological cure rates in the two regimens (around 100%). More patients relapsed in the fully intermittent regimen compared with the daily regimen, but the size of the study was insufficient to be clear if this was a true effect or had arisen by chance.</P>
<P>There was no indication of differential adverse reactions or the development of in vitro drug resistance during chemotherapy. The cure rate appeared to be as high in participants with pretreatment drug resistant strains of <I>Mycobacterium tuberculosis </I>as in those with pretreatment drug sensitive strains although the power of the study to detect a difference in these two subgroups was low. No pretreatment multiple drug resistant strains were identified.</P>
<P>These conclusions can, however, only be tentative because only one study with significant methodological deficiencies was identified. These consisted mainly in the lack of an intention-to-treat analysis and a lack of detail on the randomization and concealment process.</P>
<P>Further studies in larger groups of patients are warranted to firmly establish the apparent equivalent effectiveness of fully intermittent short course chemotherapy with respect to bacteriological cure. It is, however, difficult to assess how urgent such studies are in the light of the accumulated evidence from cohort studies that fully intermittent drug administration (as defined in this review) is well tolerated and effective, with cure rates of 80 to 100% in studies which have included HIV negative patients (<LINK REF="REF-Roumania-1977" TYPE="REFERENCE">Roumania 1977</LINK>, <LINK REF="REF-Dutt-1979" TYPE="REFERENCE">Dutt 1979</LINK>, <LINK REF="REF-Cohn-1990" TYPE="REFERENCE">Cohn 1990</LINK>, <LINK REF="REF-Manalo-1990" TYPE="REFERENCE">Manalo 1990</LINK>, <LINK REF="REF-Hong-Kong-1991a" TYPE="REFERENCE">Hong Kong 1991a</LINK>, <LINK REF="REF-Hong-Kong-1991b" TYPE="REFERENCE">Hong Kong 1991b</LINK>, <LINK REF="REF-Sedlaczek-1995" TYPE="REFERENCE">Sedlaczek 1995</LINK>, <LINK REF="REF-China-1996" TYPE="REFERENCE">China 1996</LINK>, <LINK REF="REF-Neher-1996" TYPE="REFERENCE">Neher 1996</LINK>, <LINK REF="REF-Bechan-1997" TYPE="REFERENCE">Bechan 1997</LINK>), predominantly HIV negative patients (<LINK REF="REF-Caminero-1996" TYPE="REFERENCE">Caminero 1996</LINK>, <LINK REF="REF-Wilkinson-1997c" TYPE="REFERENCE">Wilkinson 1997c</LINK>) and significant numbers of HIV positive patients (<LINK REF="REF-Alwood-1994" TYPE="REFERENCE">Alwood 1994</LINK>, <LINK REF="REF-Davies-1999" TYPE="REFERENCE">Davies 1999</LINK>). Nonetheless it will be important to include HIV positive participants in such studies as the effectiveness of intermittent therapy for these individuals should not automatically be extrapolated from evidence from those who are HIV negative.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-18 16:31:24 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-08-18 16:31:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Reviewers' opinion</HEADING>
<P>Fully intermittent regimens have been advocated on the basis of several uncontrolled cohort studies with good outcomes. However, from this review, only one study has directly compared outcomes between daily and intermittent regimens. The number of patients randomized in this one comparison are too small to prove either that one form of dosing is superior or that they are equivalent.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-18 16:31:19 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Reviewers' opinion</HEADING>
<P>Research with HIV positive participants is required to be sure of the effectiveness of regimens in these groups, as extrapolation of the evidence from HIV negative patients may not be valid.</P>
<P>Large studies comparing fully intermittent regimens directly with daily regimens are required with adequate follow-up to at least 12 months post chemotherapy to establish equivalence between these two forms of drug administration.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>To the referees of this review for their rapid and constructive comments.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>We certify that we have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of the review (eg employment, consultancy, stock ownership, honoraria, expert testimony).<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-08 13:12:29 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-Kong-1981" NAME="Hong Kong 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong Kong Chest Service/ British Medical Research Council</AU>
<TI>Controlled trial of four thrice weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<PG>171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Brazil-1989" NAME="Brazil 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Castelo A, Jardim JR, Goihman S, Kalckman AS, Dalboni MA, da Silva EA, Haynes RB. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. Lancet 1989;2:1173-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castelo A, Jardim JR, Goihman S, Kalckman AS, Dalboni MA, da Silva EA, et al</AU>
<TI>Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>1173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-Kong-1974" NAME="Hong Kong 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council</AU>
<TI>A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong</TI>
<SO>Tubercle</SO>
<YR>1974</YR>
<VL>55</VL>
<PG>1-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-Kong-1982" NAME="Hong Kong 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong Kong Chest Service/British Medical Research Council</AU>
<TI>Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months</TI>
<SO>Tubercle</SO>
<YR>1982</YR>
<VL>63</VL>
<PG>89-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-Kong-1987" NAME="Hong Kong 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong Kong Chest Service/British Medical Research Council</AU>
<TI>Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1987</YR>
<VL>136</VL>
<PG>1339-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-1990" NAME="India 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Kumar L, Dhand R, Singhi PD, Rao KLN, Katariya S. A randomised trial of fully intermittent Vs.daily followed by intermittent short course chemotherapy for childhood tuberculosis. Paediatr Infect Dis J 1990;9:802-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar L, Dhand R, Singhi PD, Rao KLN, Katariya S</AU>
<TI>A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis</TI>
<SO>Paediatric Infectious Disease Journal</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>11</NO>
<PG>802-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korea-1988" NAME="Korea 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong YP, Kim SC, Chang SC, Kim SJ, Jin BW, Park CD</AU>
<TI>Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions</TI>
<SO>Tubercle</SO>
<YR>1988</YR>
<VL>69</VL>
<PG>241-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-2000" NAME="South Africa 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Te Water Naude JM, Donald PR, Hussey GD, Kibel MA, Louw A, Perkins DR, et al</AU>
<TI>Twice weekly vs. daily chemotherapy for childhood tuberculosis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>5</NO>
<PG>405-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-08 13:12:29 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-08 13:12:29 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alwood-1994" NAME="Alwood 1994" TYPE="JOURNAL_ARTICLE">
<AU>Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE</AU>
<TI>Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients</TI>
<SO>AIDS</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>8</NO>
<PG>1103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-1993" MODIFIED="2008-08-18 16:48:35 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1993" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Approaches to improving adherence to antituberculosis therapy--South Carolina and New York, 1986-1991</TI>
<SO>MMWR. Morbidy and Mortality Weekly Report</SO>
<YR>1993</YR>
<VL>42</VL>
<PG>74-5,81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bechan-1997" MODIFIED="2008-08-18 16:48:40 +0100" MODIFIED_BY="[Empty name]" NAME="Bechan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bechan S, Connolly C, Short GM, Standing E, Wilkinson D</AU>
<TI>Directly observed therapy for tuberculosis given twice weekly in the workplace in urban South Africa</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<PG>704-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1984" MODIFIED="2008-08-18 16:48:46 +0100" MODIFIED_BY="[Empty name]" NAME="BTS 1984" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Society</AU>
<TI>A controlled trial of 6 months chemotherapy in pulmonary tuberculosis, final report : results during the 36 months after the end of chemotherapy and beyond</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1984</YR>
<VL>78</VL>
<PG>330-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caminero-1996" MODIFIED="2008-08-18 16:48:51 +0100" MODIFIED_BY="[Empty name]" NAME="Caminero 1996" TYPE="JOURNAL_ARTICLE">
<AU>Caminero JA, Pavon JM, Rodriguez de Castro F, Diaz F, Julia G, Cayla JA, et al</AU>
<TI>Evaluation of a directly observed six month fully intermittent treatment regimens for tuberculosis in patients suspected of poor compliance</TI>
<SO>Thorax</SO>
<YR>1996</YR>
<VL>51</VL>
<PG>1130-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaulk-1995" MODIFIED="2008-08-18 16:48:59 +0100" MODIFIED_BY="[Empty name]" NAME="Chaulk 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE</AU>
<TI>Eleven years of community-based directly observed therapy for tuberculosis</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>274</VL>
<NO>12</NO>
<PG>945-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-China-1996" MODIFIED="2008-08-18 16:49:05 +0100" MODIFIED_BY="[Empty name]" NAME="China 1996" TYPE="JOURNAL_ARTICLE">
<AU>China Tuberculosis Control Collaboration</AU>
<TI>Results of a directly observed short course chemotherapy in 112842 Chinese patients with smear positive tuberculosis</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>343</VL>
<PG>358-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2002" MODIFIED="2008-10-08 13:12:29 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2002" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Optimal search strategy. Cochrane Reviewers' Handbook 4.1.5 [updated April 2002]; Appendix 5c</TI>
<SO>In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software; 2002, Issue 4</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohn-1990" MODIFIED="2008-08-18 16:49:10 +0100" MODIFIED_BY="[Empty name]" NAME="Cohn 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA</AU>
<TI>A 62-dose, 6 months therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed and cost-effective regimen</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1990</YR>
<VL>112</VL>
<PG>407-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowle-1986" MODIFIED="2008-08-18 16:49:20 +0100" MODIFIED_BY="[Empty name]" NAME="Crowle 1986" TYPE="JOURNAL_ARTICLE">
<AU>Crowle AJ, Sbarbaro JA, May MH</AU>
<TI>Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1986</YR>
<VL>134</VL>
<PG>1052-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-1999" NAME="Davies 1999" TYPE="JOURNAL_ARTICLE">
<AU>Davies GR, Connolly C, Sturm AW, McAdam KP, Wilkinson D</AU>
<TI>Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa</TI>
<SO>AIDS</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>7</NO>
<PG>811-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dolin-1994" MODIFIED="2008-08-18 16:49:25 +0100" MODIFIED_BY="[Empty name]" NAME="Dolin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dolin PJ, Raviglione MC, Kochi A</AU>
<TI>Global tuberculosis incidence and mortality during 1990-2000</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1994</YR>
<VL>72</VL>
<PG>213-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dutt-1979" MODIFIED="2008-08-18 16:49:29 +0100" MODIFIED_BY="[Empty name]" NAME="Dutt 1979" TYPE="JOURNAL_ARTICLE">
<AU>Dutt AK, Jones L, Stead WW</AU>
<TI>Short-course chemotherapy for tuberculosis with largely twice-weekly isoniazid-rifampin</TI>
<SO>Chest</SO>
<YR>1979</YR>
<VL>75</VL>
<PG>441-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-E_x0026_C-Africa-1983" MODIFIED="2008-08-18 16:49:33 +0100" MODIFIED_BY="[Empty name]" NAME="E&amp;C Africa 1983" TYPE="JOURNAL_ARTICLE">
<AU>East &amp; Central African/British Medical Research Councils' Fifth Collaborative Study</AU>
<TI>Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis</TI>
<SO>Tubercle</SO>
<YR>1983</YR>
<VL>64</VL>
<PG>153-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enarson-1996" MODIFIED="2008-08-18 16:49:51 +0100" MODIFIED_BY="[Empty name]" NAME="Enarson 1996" TYPE="BOOK">
<AU>Enarson DA, Rieder HL, Arnadottir T, Trebucq A</AU>
<SO>Tuberculosis guide for low income countries</SO>
<YR>1996</YR>
<EN>4th</EN>
<PB>pmi Verlagsgruppe</PB>
<CY>Frankfurt</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grzybowski-1975" MODIFIED="2008-08-18 16:49:53 +0100" MODIFIED_BY="[Empty name]" NAME="Grzybowski 1975" TYPE="JOURNAL_ARTICLE">
<AU>Grzybowski S, Barnett GD, Styblo K</AU>
<TI>Contacts of cases of active pulmonary tuberculosis</TI>
<SO>Bulletin of the International Union Against Tuberculosis</SO>
<YR>1975</YR>
<VL>50</VL>
<PG>90-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harries-1996" MODIFIED="2008-08-18 16:49:55 +0100" MODIFIED_BY="[Empty name]" NAME="Harries 1996" TYPE="JOURNAL_ARTICLE">
<AU>Harries AD, Nyong'Onya Mbewe L, Salaniponi FM, Nyangulu DS, Veen J, Ringdal T, et al</AU>
<TI>Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>807-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hong-Kong-1991a" MODIFIED="2008-08-18 16:49:58 +0100" MODIFIED_BY="[Empty name]" NAME="Hong Kong 1991a" TYPE="JOURNAL_ARTICLE">
<AU>HongKong Chest Service / British Medical Research Council</AU>
<TI>Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide</TI>
<SO>Am Rev Respir Dis</SO>
<YR>1991</YR>
<VL>143</VL>
<PG>700-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hong-Kong-1991b" MODIFIED="2008-08-18 16:50:02 +0100" MODIFIED_BY="[Empty name]" NAME="Hong Kong 1991b" TYPE="JOURNAL_ARTICLE">
<AU>Hong Kong Chest Service / Tuberculosis Research Centre, Madras / British Medical Research Council</AU>
<TI>A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1991</YR>
<VL>143</VL>
<PG>262-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manalo-1990" MODIFIED="2008-08-18 16:50:05 +0100" MODIFIED_BY="[Empty name]" NAME="Manalo 1990" TYPE="JOURNAL_ARTICLE">
<AU>Manalo F, Tan F, Sbarbaro JA, Iseman MD</AU>
<TI>Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1990</YR>
<VL>142</VL>
<PG>1301-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neher-1996" MODIFIED="2008-08-18 16:50:07 +0100" MODIFIED_BY="[Empty name]" NAME="Neher 1996" TYPE="JOURNAL_ARTICLE">
<AU>Neher A, Breyer G, Shrestha B, Feldmann K</AU>
<TI>Directly observed short-course chemotherapy in the Kathmandu valley</TI>
<SO>Tubercle and Lung Disease</SO>
<YR>1996</YR>
<VL>77</VL>
<PG>302-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roumania-1977" NAME="Roumania 1977" TYPE="JOURNAL_ARTICLE">
<AU>Tuberculosis Research Institute, Bucharest</AU>
<TI>Trial of two intermittent short-course regimens (78 doses) in the initial treatment of pulmonary tuberculosis</TI>
<SO>Tubercle</SO>
<YR>1977</YR>
<VL>58</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sedlaczek-1995" MODIFIED="2008-08-18 16:50:15 +0100" MODIFIED_BY="[Empty name]" NAME="Sedlaczek 1995" TYPE="JOURNAL_ARTICLE">
<AU>Sedlaczek AM, Serwatowski P, Spiewak W</AU>
<TI>Evaluation of the efficacy of treatment for smear-positive pulmonary tuberculosis with early introduction of the interrupting method - preliminary report</TI>
<SO>Pneumonologia i Alergologia Polska</SO>
<YR>1995</YR>
<VL>63</VL>
<PG>293-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singapore-1981" NAME="Singapore 1981" TYPE="JOURNAL_ARTICLE">
<AU>Singapore Tuberculosis Service/British Medical Research Council</AU>
<TI>Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months</TI>
<SO>Tubercle</SO>
<YR>1981</YR>
<VL>62</VL>
<PG>95-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weis-1994" MODIFIED="2008-08-18 16:50:19 +0100" MODIFIED_BY="[Empty name]" NAME="Weis 1994" TYPE="JOURNAL_ARTICLE">
<AU>Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al</AU>
<TI>The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>1179-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1996" MODIFIED="2008-08-18 16:50:23 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1996" TYPE="JOURNAL_ARTICLE">
<AU>Global Tuberculosis Programme</AU>
<TI>Tuberculosis notification update</TI>
<SO>World Health Organization Weekly Epidemiological Record</SO>
<YR>1996</YR>
<VL>71</VL>
<NO>9</NO>
<PG>65-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-1997a" MODIFIED="2008-08-18 16:50:28 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson D, Floyd K, Gilks CF</AU>
<TI>Cost and cost-effectiveness of alternative tuberculosis management strategies in South Africa--implications for policy</TI>
<SO>South African Medical Journal</SO>
<YR>1997</YR>
<VL>87</VL>
<PG>451-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-1997b" MODIFIED="2008-08-18 16:50:31 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson D, Davies GR</AU>
<TI>Coping with Africa's increasing tuberculosis burden: are community supervisors an essential component of the DOT strategy?</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>7</NO>
<PG>700-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-1997c" MODIFIED="2008-08-18 16:50:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 1997c" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson D, Anderson E, Davies GR, Sturm AW, McAdam KP</AU>
<TI>Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>1</NO>
<PG>87-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-08 13:11:34 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-08 13:10:52 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-10-08 13:10:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hong-Kong-1981">
<CHAR_METHODS>
<P>Randomized controlled trial, allocation method not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-08 13:10:35 +0100" MODIFIED_BY="[Empty name]">
<P>Adult attenders at chest clinic with smear positive pulmonary tuberculosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-18 16:46:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized to 5 regimens</P>
<P>Only one comparison relevant to this review:</P>
<P>Group 1: Daily isoniazid, rifampicin, pyrazinamide, and ethambutol for 6 months<BR/>Group 2: Same drugs as in group 1 but given 3 times a week for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Microbiological cure, mortality, sterility, recurrence, resistance, adherence, and toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-08 13:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>No human immunodeficiency virus (HIV) positive participants (pre-HIV epidemic)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-08 13:11:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Brazil-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long duration of initial daily therapy for the intermittent group (2 months).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hong-Kong-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long duration of treatment (more than 9 months).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 13:11:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hong-Kong-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 13:11:29 +0100" MODIFIED_BY="[Empty name]">
<P>This is the same study as the one included (<LINK REF="STD-Hong-Kong-1981" TYPE="STUDY">Hong Kong 1981</LINK>) but details a longer follow-up period (18 months after stopping treatment). In our review relapse of disease has been defined within the context of a 12 month follow-up period after stopping treatment, so further episodes of recurrent disease beyond 12 months do not add to the analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 13:11:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hong-Kong-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 13:11:34 +0100" MODIFIED_BY="[Empty name]">
<P>This is the same study as the one included (<LINK REF="STD-Hong-Kong-1981" TYPE="STUDY">Hong Kong 1981</LINK>) but detailing longer follow-up to 5 years. Once again it is difficult to classify episodes of disease in this time period as arising because of reinfection or relapse.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-18 16:47:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-India-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-18 16:47:49 +0100" MODIFIED_BY="[Empty name]">
<P>Conducted in children aged 1 to 15 years.</P>
<P>Included participants with pulmonary, lymph node, and disseminated tuberculosis.</P>
<P>Daily treatment was for 2 months followed by 4 months of twice weekly therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Korea-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long duration of treatment (more than 9 months).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-18 16:47:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-South-Africa-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-18 16:47:52 +0100" MODIFIED_BY="[Empty name]">
<P>Study conducted in children with all forms of intrathoracic tuberculosis.</P>
<P>Tuberculosis was confirmed in 4%, was probable in 94%, and was suspected in 2% of the patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-18 16:46:16 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-18 16:46:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-18 16:39:26 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-18 16:39:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Thrice weekly tuberculosis treatment versus daily treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.096684717510096" CI_START="0.8954415520499595" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9909677419354839" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="199" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.04008179154384865" LOG_CI_START="-0.04796275649344526" LOG_EFFECT_SIZE="-0.0039404824747982905" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8607350552150017" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="0.17543854570176268">
<NAME>Cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="174" EVENTS_2="168" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="174" TOTAL_2="168" WEIGHT="0.0" Z="0.0">
<NAME>Drug sensitive pretreatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="174" EVENTS_2="168" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="744" O_E="0.0" SE="0.0" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="174" TOTAL_2="168" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.096684717510096" CI_START="0.8954415520499595" DF="0.0" EFFECT_SIZE="0.9909677419354839" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.04008179154384865" LOG_CI_START="-0.04796275649344526" LOG_EFFECT_SIZE="-0.0039404824747982905" NO="2" P_CHI2="1.0" P_Z="0.8607350552150017" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.0" Z="0.17543854570176268">
<NAME>Drug resistant pretreatment</NAME>
<DICH_DATA CI_END="1.0966847175100958" CI_START="0.8954415520499597" EFFECT_SIZE="0.9909677419354839" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.04008179154384857" LOG_CI_START="-0.047962756493445155" LOG_EFFECT_SIZE="-0.0039404824747982905" ORDER="745" O_E="0.0" SE="0.05171780334464804" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="25" TOTAL_2="32" VAR="0.002674731182795688" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="89.66629984812226" CI_START="0.16169420099431914" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.8076923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.9526292486181112" LOG_CI_START="-0.7913055553646473" LOG_EFFECT_SIZE="0.5806618466267319" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4068094460989702" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="0.8295213901824662">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="174" TOTAL_2="168" WEIGHT="0.0" Z="0.0">
<NAME>Drug sensitive pretreatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="746" O_E="0.0" SE="0.0" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="174" TOTAL_2="168" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="89.66629984812226" CI_START="0.16169420099431914" DF="0.0" EFFECT_SIZE="3.8076923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="1.9526292486181112" LOG_CI_START="-0.7913055553646473" LOG_EFFECT_SIZE="0.5806618466267319" NO="2" P_CHI2="1.0" P_Z="0.4068094460989702" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.0" Z="0.8295213901824662">
<NAME>Drug resistant pretreatment</NAME>
<DICH_DATA CI_END="89.66629984812226" CI_START="0.1616942009943192" EFFECT_SIZE="3.8076923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9526292486181112" LOG_CI_START="-0.7913055553646472" LOG_EFFECT_SIZE="0.5806618466267319" ORDER="747" O_E="0.0" SE="1.6118008865558109" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="25" TOTAL_2="32" VAR="2.597902097902098" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.748537653746388E-4" CI_END="24.09767204301562" CI_START="0.6637043513908587" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.999216147364295" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.3819750895580376" LOG_CI_START="-0.17802533501903356" LOG_EFFECT_SIZE="0.6019748772695022" METHOD="MH" MODIFIED="2008-08-18 16:39:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9750919795831219" P_Q="0.0" P_Z="0.13037453029357723" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="192" WEIGHT="100.0" Z="1.5126266127344294">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="34.7549868989169" CI_START="0.4436769936690897" DF="0.0" EFFECT_SIZE="3.926829268292683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.5410171291359986" LOG_CI_START="-0.3529330905117702" LOG_EFFECT_SIZE="0.5940420193121142" NO="1" P_CHI2="1.0" P_Z="0.21888637355039176" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="161" WEIGHT="70.70350774054478" Z="1.229494789331606">
<NAME>Drug sensitive pretreatment</NAME>
<DICH_DATA CI_END="34.7549868989169" CI_START="0.4436769936690897" EFFECT_SIZE="3.926829268292683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5410171291359986" LOG_CI_START="-0.3529330905117702" LOG_EFFECT_SIZE="0.5940420193121142" ORDER="748" O_E="0.0" SE="1.112515734225888" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="164" TOTAL_2="161" VAR="1.2376912589001667" WEIGHT="70.70350774054478"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.93437673650911" CI_START="0.1778900389736524" DF="0.0" EFFECT_SIZE="4.173913043478261" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="1.9909351637784252" LOG_CI_START="-0.749848369734474" LOG_EFFECT_SIZE="0.6205433970219755" NO="2" P_CHI2="1.0" P_Z="0.3748019156632941" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="31" WEIGHT="29.296492259455224" Z="0.8875146060501445">
<NAME>Drug resistant pretreatment</NAME>
<DICH_DATA CI_END="97.93437673650902" CI_START="0.17789003897365246" EFFECT_SIZE="4.173913043478261" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.990935163778425" LOG_CI_START="-0.7498483697344739" LOG_EFFECT_SIZE="0.6205433970219755" ORDER="749" O_E="0.0" SE="1.6099498146827749" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="22" TOTAL_2="31" VAR="2.591938405797101" WEIGHT="29.296492259455224"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-08-18 16:39:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="200" WEIGHT="0.0" Z="0.0">
<NAME>Resistance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="174" TOTAL_2="168" WEIGHT="0.0" Z="0.0">
<NAME>Drug sensitive pretreatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="750" O_E="0.0" SE="0.0" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="174" TOTAL_2="168" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Drug resistant pretreatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="751" O_E="0.0" SE="0.0" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="25" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.096684717510096" CI_START="0.8954415520499595" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9909677419354839" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="199" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.04008179154384865" LOG_CI_START="-0.04796275649344526" LOG_EFFECT_SIZE="-0.0039404824747982905" METHOD="MH" MODIFIED="2008-08-18 16:39:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.8607350552150017" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="0.17543854570176268">
<NAME>Adherence</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="174" EVENTS_2="168" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="174" TOTAL_2="168" WEIGHT="0.0" Z="0.0">
<NAME>Drug sensitive pretreatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="174" EVENTS_2="168" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="752" O_E="0.0" SE="0.0" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="174" TOTAL_2="168" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.096684717510096" CI_START="0.8954415520499595" DF="0.0" EFFECT_SIZE="0.9909677419354839" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.04008179154384865" LOG_CI_START="-0.04796275649344526" LOG_EFFECT_SIZE="-0.0039404824747982905" NO="2" P_CHI2="1.0" P_Z="0.8607350552150017" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.0" Z="0.17543854570176268">
<NAME>Drug resistant pretreatment</NAME>
<DICH_DATA CI_END="1.0966847175100958" CI_START="0.8954415520499597" EFFECT_SIZE="0.9909677419354839" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.04008179154384857" LOG_CI_START="-0.047962756493445155" LOG_EFFECT_SIZE="-0.0039404824747982905" ORDER="753" O_E="0.0" SE="0.05171780334464804" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="25" TOTAL_2="32" VAR="0.002674731182795688" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.592081542947733" CI_START="0.6177267510703702" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.991701244813278" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.2019653075884078" LOG_CI_START="-0.20920359084186918" LOG_EFFECT_SIZE="-0.003619141626730686" METHOD="MH" MODIFIED="2008-08-18 16:39:26 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.9724756351228527" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="241" TOTAL_2="239" WEIGHT="100.0" Z="0.0345035204288181">
<NAME>Toxicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.592081542947733" CI_START="0.6177267510703702" EFFECT_SIZE="0.991701244813278" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.2019653075884078" LOG_CI_START="-0.20920359084186918" LOG_EFFECT_SIZE="-0.003619141626730686" ORDER="754" O_E="0.0" SE="0.24152264625681716" STUDY_ID="STD-Hong-Kong-1981" TOTAL_1="241" TOTAL_2="239" VAR="0.05833318865489563" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>